VeriTeQ Corporation to Be Featured in Interview on
Post# of 94265
Posted On: 01/06/2014 8:42:35 AM
VeriTeQ Corporation to Be Featured in Interview on Fox Business and Bloomberg Television
Interview with “The RedChip Money Report: Small Stocks Big Money” will be broadcast in January
VeriTeQ Corporation (“VeriTeQ”) (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it is featured in an interview on “The RedChip Money Report: Small Stocks Big Money”, which will be broadcast on Fox Business and Bloomberg television networks. The interview can currently be viewed online at http://youtu.be/F-UC5lBp2Ns.
Scott R. Silverman, VeriTeQ’s Chairman and Chief Executive Officer, was recently interviewed by “The RedChip Money Report: Small Stocks Big Money” host Dave Gentry, and discusses the Company’s technologies and market opportunities for 2014 and beyond, including U.S. mandates that are expected to drive product adoption.
Produced in RedChip's state-of-the-art studio in Orlando, "The RedChip Money Report: Small Stocks Big Money" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and president of RedChip, an international small-cap research firm and an Inc. 5000 company. Mr. Gentry has made multiple guest appearances on both CNBC and Fox Business News and has been a consultant to hundreds of public companies.
“The RedChip Money Report: Small Stocks Big Money” now reaches more than 215 million homes across the U.S., Europe and Asia through Bloomberg and Fox Business.
About VeriTeQ
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.
Statements in this press release and in the RedChip Money Report: Small Stocks Big Money interview about our future expectations, including, without limitation, the likelihood that the Company will meet certain revenue projections and gross margin projections; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to commercially launch its Q Inside Safety Technology; the Company’s ability to target the UDI sector and medical device manufacturers; VeriTeQ’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ’s Forms 10-Q, filed on August 9, 2013 and November 14, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
VeriTeQ
Allison Tomek, 561-846-7003
atomek@veriteqcorp.com
Interview with “The RedChip Money Report: Small Stocks Big Money” will be broadcast in January
VeriTeQ Corporation (“VeriTeQ”) (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it is featured in an interview on “The RedChip Money Report: Small Stocks Big Money”, which will be broadcast on Fox Business and Bloomberg television networks. The interview can currently be viewed online at http://youtu.be/F-UC5lBp2Ns.
Scott R. Silverman, VeriTeQ’s Chairman and Chief Executive Officer, was recently interviewed by “The RedChip Money Report: Small Stocks Big Money” host Dave Gentry, and discusses the Company’s technologies and market opportunities for 2014 and beyond, including U.S. mandates that are expected to drive product adoption.
Produced in RedChip's state-of-the-art studio in Orlando, "The RedChip Money Report: Small Stocks Big Money" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and president of RedChip, an international small-cap research firm and an Inc. 5000 company. Mr. Gentry has made multiple guest appearances on both CNBC and Fox Business News and has been a consultant to hundreds of public companies.
“The RedChip Money Report: Small Stocks Big Money” now reaches more than 215 million homes across the U.S., Europe and Asia through Bloomberg and Fox Business.
About VeriTeQ
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.
Statements in this press release and in the RedChip Money Report: Small Stocks Big Money interview about our future expectations, including, without limitation, the likelihood that the Company will meet certain revenue projections and gross margin projections; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to commercially launch its Q Inside Safety Technology; the Company’s ability to target the UDI sector and medical device manufacturers; VeriTeQ’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ’s Forms 10-Q, filed on August 9, 2013 and November 14, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
VeriTeQ
Allison Tomek, 561-846-7003
atomek@veriteqcorp.com
(0)
(0)